Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fosmidomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosmidomycin SCHEMBL4432380 | 0.98 | TYMS (0.46) | TYMSS1PR2S1PR1S1PR3S1PR5 | |
| Fosmidomycin SCHEMBL11438018 | 0.98 | TYMS (0.46) | TYMSS1PR2S1PR1S1PR3S1PR5 | |
| Fosmidomycin SCHEMBL14485270 | 0.92 | S1PR2 (0.50) | S1PR2S1PR1S1PR3S1PR5 | |
| Fosmidomycin SCHEMBL11434157 | 0.92 | LMNA (0.50) | TYMS | |
| SCHEMBL10795849 | 0.91 | LPAR3 (0.45) | TYMSS1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL11313004 | 0.91 | LPAR3 (0.45) | TYMSS1PR2S1PR1S1PR3S1PR5 | |
| Fosmidomycin SCHEMBL10824609 | 0.89 | ALDH1A1 (0.48) | S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL4322762 | 0.86 | TYMS (0.39) | TYMS | |
| SCHEMBL18161031 | 0.83 | GABBR2 (0.45) | — | |
| Fosmidomycin SCHEMBL10350781 | 0.82 | S1PR2 (0.35) | S1PR2S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1760 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3829715-B1 | QUATERNARY AMMONIUM SALTS OF NICOTINIC ACID AND NICOTINAMIDE MONONUCLOETIDES AND RIBOSIDES AS ANTI-AGING AGENTS | Jumpstart Fertility Pty Ltd (AU) | 2025-12-03 | — | — | EP | claimed |
| EP-3794005-B1 | INORGANIC SALTS OF NICOTINIC ACID MONONUCLEOTIDE AS ANTI-AGING AGENTS | Jumpstart Fertility Pty Ltd (AU) | 2025-10-22 | — | — | EP | claimed |
| US-20250179429-A1 | CELL CULTURE MEDIUM | UPSIDE BIOTECHNOLOGIES LIMITED (NZ) | 2025-06-05 | — | — | US | claimed |
| CN-113498416-B | Inorganic salts of nicotinic acid mononucleotide as anti-aging agents | 江普斯塔特生育有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-118415161-A | Improved erythrocyte cryoprotectant containing D-trehalose and preparation method and application thereof | 华南理工大学 | 2024-08-02 | — | — | CN | claimed |
| WO-2024126936-A1 | STACKED PRINTED PIEZOELECTRIC DEVICE | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2024-06-20 | — | — | WO | claimed |
| US-20240173460-A1 | STORAGE SOLUTIONS FOR MAINTAINING OF AXONAL VIABILITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-30 | — | — | US | claimed |
| US-20240017234-A1 | IMPROVED MICROCAPSULES AND METHOD FOR THE PRODUCTION AND USE THEREOF | Follman GmbH & Co. KG (DE) | 2024-01-18 | — | — | US | claimed |
| US-20230413828-A1 | BIOHERBICIDES FOR CONTROLLING ONE OR MORE PLANT SPECIES | AGROSPHERES, INC. | 2023-12-28 | — | — | US | claimed |
| US-4846872-A | FOSMIDOMYCIN, AMETRYN, DIURON | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-11 | — | — | US | claimed |
| EP-0256785-A2 | Herbicide | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-24 | — | — | EP | claimed |
| EP-0009686-B1 | ANTIBACTERIAL COMPOSITION COMPRISING A PHOSPHONIC ACID DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-06-23 | — | — | EP | claimed |
| US-4330529-A | SYNERGISTIC ACTIVITY OF PHOSPHONIC ACID DERIVATIVE AND CEPHALOSPOR | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-05-18 | — | — | US | claimed |
| US-4268503-A | ANTIBIOTIC AND PHOSPHONIC ACID DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-19 | — | — | US | claimed |
| US-4210635-A | A PHOSPHONIC ACID DERIVATIVE AND AN ANTIBIOTIC | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-07-01 | — | — | US | claimed |
| EP-0009686-A1 | Antibacterial composition comprising a phosphonic acid derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-16 | — | — | EP | claimed |
| US-4196193-A | 3-(N-ACYL-N-HYDROXYAMINO/PROPYLPHOSPHONIC ACID, NOCARDICIN A, SYNERGISTIC | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-01 | — | — | US | claimed |
| US-4182758-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-01-08 | — | — | US | claimed |
| EP-0003618-A1 | Antibacterial composition and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-08-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179429-A1 | CELL CULTURE MEDIUM | NEFM, KRT18, CUTA | TYMS 3833/4885S1PR2 3398/4885S1PR1 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.